Erin has significant experience representing clients in ANDA cases and handles all phases of federal court litigation, including early case assessment, claim construction, fact and expert discovery, trial, and appeal. She also represents clients in contested proceedings before the USPTO, including inter partes reviews (IPRs) and interference proceedings. Her Patent Trial and Appeal Board (PTAB) work includes developing strategies to challenge or defend patent claims and coordinating those proceedings with related district court litigation to advance clients' overall positions.
Erin also assists clients in coordinating parallel ex-U.S. patent litigation and opposition proceedings, helping to align strategies across jurisdictions, protect global intellectual property portfolios, and secure freedom to operate.
Erin handles IP due diligence investigations for high-profile acquisitions, providing critical assessments of patent portfolios and associated risks in complex corporate transactions. She also handles patent prosecution and opinion work, including ex parte prosecution appeals before the USPTO.
In the pharmaceutical space, Erin's experience spans therapeutic areas that include chemotherapies, hormone-receptor antagonists, anti-infectives, antivirals, and ophthalmic drugs. Her technical background and laboratory experience give her a scientific foundation from which to engage deeply with technical evidence, communicate effectively with inventors and experts, and craft persuasive arguments grounded in a thorough understanding of the matter at hand. Having seen what pharmaceutical research and development looks like in practice, she brings an in-house perspective that helps her understand her clients' businesses.
Erin began her legal career as an associate at Fitzpatrick, Cella, Harper & Scinto, which is now part of Venable.